18/11/2014 - General information
The platform for the analysis of human diseases and their genes DisGeNET, developed by the Integrative Biomedical Informatics research group at GRIB (IMIM-UPF) appears for the first time in the Linking Open Data (LOD) linking diagram. This type of diagram shows sets of data in Linked Data format, which is used by the World Wide Web to link structured and related data. Linked Data is the best way to showcase, share and connect data, information and knowledge on the semantic web through technologies such as Uniform Resource Identifiers (or URIs, web resource identifiers) andResource Description Framework (or RDF, a model to represent information in a structured way).
Més informació "DisGeNET included in the Linking Open Data (LOD) diagram"
13/11/2014 - Press release
A study by the international consortium The Myocardial Infarction Genetics (MIGen) with the participation of researchers from the Hospital del Mar Medical Research Institute (IMIM) has analysed the genetic characteristics in more than 110,000 people and has identified, for the first time, 15 mutations in gene NPC1L1. The existence of any of these mutations has been associated to a reduction in the levels of LDL cholesterol or “bad cholesterol” as well as protecting against the risk of having an acute myocardial infarction. The results are published on-line in the prestigious journal The New England Journal of Medicine.
10/10/2014 - Institutional news
The Science and Innovation Ministry through the Science and TechnologySpanish Foundation launched last October 9 at the headquarters of the Carlos III Institute thePrecipita platform, designed to promote special interesting projects to be funded through micro-patronage (crowdfunding), small contributions from individuals. One of the selected projects presented is Brainful Legends, a videogame for cognitive stimulation, science-based, modern, funny and, above all, accessible to all people with intellectual disabilities.
Més informació "Precipita platform presentation and the video game Brainful Legends"
17/09/2014 - Press release
Researchers in Biomedical Informatics at IMIM (Hospital del Mar Medical Research Institute) and at the Universitat Politècnica de Catalunya (UPC) have recently published a study in eLife showing that RNA called non-coding (IncRNA) plays an important role in the evolution of new proteins, some of which could have important cell functions yet to be discovered. Ribosomes produce proteins from the instructions found in an RNA molecule. However, only 2% of the human genome is RNA containing information for the synthesis of proteins, meaning it is coding. Other parts of the genome that are transcribed could be “evolutionary noise”, parts of the DNA that are copied to RNA randomly but with no concrete biological function. Now, a new sequencing technique has revealed that many of these transcripts (IncRNAs) may also translate into proteins, leading to an intense debate.
09/09/2014 - Press release
Mental disorders and brain disease represent a high cost in Europe and around the world. Researchers from IMIM (Hospital del Mar Medical Research Institute) have recently published in the PLOS ONE journal the results of a study that estimates that the cost of disorders of the brain in Spain is the equivalent of 84 billion Euros per year. This figure is far higher than the Spanish expenditure in health, which was 73 billion Euros in 2012. When referring to the cost of a disease, this not only includes the direct health cost – resources used for primary healthcare, specialised care, hospital stays, medication, preventive programmes, etc. –but also direct non-medical costs of these disorders and diseases –for instance, the cost of carers –and the indirect costs or potential loss of productivity for death, permanent or temporary disability, lost or decreased leisure, etc. For this study, a group of nineteen disorders and diseases of the brain were included, encompassing neurological diseases –dementia, epilepsy, headache, multiple sclerosis, Parkinson’s disease, strokes and neuromuscular diseases – and also mental diseases –anxiety disorders, humour disorders and psychotic disorders – to reach a global and individual estimate of their impact.
A study carried out by researchers from the Research programme on Biomedical Informatics (GRIB) at IMIM (Hospital del Mar Medical Research Institute) and the UPF has used new human genetic data to learn more about mutations that may have conferred a selective advantage to humans over the past 5 million years of evolution. This provides researchers with a new vision on human evolution. The availability of the genetic variants in a large number of people, through initiatives such as the Project 1000 Genomes, is useful not only to understand the genetic basis of diseases, but also to carry out research on the human evolution. According to Mar Albà, an ICREA professor and the coordinator of the IMIM research group on Evolutionary Genomics “This variation provides us with a measure on the proportion of the amino acid changes seen typically in a protein while it maintains its function. Once we have this value, we can then count the differences with the ancestral protein in humans and chimpanzees and if we find there have been more changes than expected, this is because the function of the protein may have changed during human evolution”.
30-06-2014 - Press release
Researchers from IMIM (Hospital del Mar Medical Research Institute) have identified a new protein, galectin-1, as a possible therapeutic target for pancreatic cancer. For the first time they have demonstrated the effects of the inhibition of this protein in mice suffering this type of cancer and the results showed an increase in survival of 20%. The work further suggests that it could be a therapeutic target with no adverse effects. This article will be published in the next edition of the Cancer Research journal, will be featured on the front page and will also be published as an author's view in OncoImmunology. Until now, the strategies for treating this tumour were aimed at attacking the tumour cells and had little success. The latest studies indicate that trying to destroy what surrounds the tumour is possibly a better strategy. “Our contribution is directed toward this, as the reduction of galectin-1 mainly affects the immune system and the cells and structure that surrounds the tumour cells, which is called the stroma. Therefore, galectin-1 as a therapeutic target has great potential”, explains Dr. Pilar Navarro, co-ordinator of the research group on molecular mechanisms of tumorigenesis of IMIM and director of the research.
05/06/2014 - Press release
Researchers from the International Stroke Genetics Consortium (ISGC), among them scientists from the Vall d'Hebron Research Institute (VHIR), the Hospital del Mar Medical Research Institute (IMIM), and the Research Foundation MutuaTerrassa (FMT) of the University Hospital MutuaTerrassa (HUMT) have identified a new gene, PMF1, involved in intracerebral haemorrhage. The finding, published in the American Journal of Human Genetics, was possible thanks to the first genome-wide association study (GWAS) on this disease.
Més informació "Researchers identify a new gene associated with haemorrhagic stroke"
09/05/2014 - Events
Understanding the complex nature of G protein-coupled receptors (GPCR) functionality and exploiting this knowledge for the design of new GPCR modulators has been the central focus of GPCR Spring Conference 2014 organized by the GRIB (IMIM-UPF) researchers Jana Selent and Maria Martí at Barcelona Biomedical Research Park (Barcelona) from 28-30th April. GPCRs are the largest family of proteins involved in signal transduction across membranes and one of the most important pharmaceutical drug target classes.
07/05/2014 - Institutional news
The European Molecular Biology Organization (EMBO) (link) has chosen 106 excelling researchers in the field of life sciences as new members of this prestigious organisation. Among these new members is Dr. Anna Bigas, the coordinator of the research group on stem cells and cancer at IMIM, and the only Spanish researcher chosen at this edition. This year’s edition has welcomed the largest number of researchers to celebrate the organization’s 50th anniversary. Out of the 106 scientists chosen, one hundred of them live in Europe and neighbour countries and six of them are associate members from China, Japan and the US. The EMBO currently has more than 1,600 scientists working in the field of life sciences, all of who have been chosen for their exceptional contributions to this field of science.
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
